NCT03361319View on ClinicalTrials.gov

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
NSCLC, RecurrentAdenocarcinoma of Lung
Interventions
DRUG

Vargatef

small molecule triple kinase inhibitor

DRUG

Abraxane

Paclitaxel formulated as albumin bound nanoparticles

OTHER

placebo

Placebo in place of Ninedanib

Sponsors
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Celgene

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT03361319 - Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma | Biotech Hunter | Biotech Hunter